Switch to:
GuruFocus has detected 8 Warning Signs with PDL BioPharma Inc $PDLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
PDL BioPharma Inc (NAS:PDLI)
Additional Paid-In Capital
$-113.7 Mil (As of Mar. 2017)

PDL BioPharma Inc's quarterly additional paid-in capital increased from Sep. 2016 ($-119.5 Mil) to Dec. 2016 ($-107.6 Mil) but then declined from Dec. 2016 ($-107.6 Mil) to Mar. 2017 ($-113.7 Mil).

PDL BioPharma Inc's annual additional paid-in capital increased from Dec. 2014 ($-119.9 Mil) to Dec. 2015 ($-118.0 Mil) and increased from Dec. 2015 ($-118.0 Mil) to Dec. 2016 ($-107.6 Mil).


Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)*Shares Outstanding

Related Terms

Shares Outstanding

Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

PDL BioPharma Inc Annual Data

AdditionalPaidInCapital 1,098.3169.2-83.9-87.4-161.8-234.1-233.2-119.9-118.0-107.6

PDL BioPharma Inc Quarterly Data

AdditionalPaidInCapital -119.9-119.4-119.2-118.5-118.0-117.2-116.5-119.5-107.6-113.7
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat